GlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML
-
Results to be presented today in poster at 58th
American Society of Hematology (ASH) Annual Meeting and Expo
The company's E-selectin antagonist, GMI-1271, showed significant progress in the Phase 1/2 clinical trial, in which clinicians are studying use of the drug candidate along with chemotherapy. For a total of 33 study participants with relapsed or refractory disease in one arm of the trial, the complete response (CR) rate was 45 percent. For 11 newly diagnosed study participants 60 or more years of age in the second arm of the trial, the CR rate was 73 percent. Thus, all study participants evaluated to date who have responded have had complete remissions; there have been no patients observed who responded with incomplete count recoveries (CRi). In addition, in elderly, newly diagnosed patients evaluated to date, the 60-day mortality rate was zero for those receiving intensive induction chemotherapy plus GMI-1271.
The results presented at the ASH meeting expand on data presented at the
"The Phase 2 data collected from the ongoing Phase 1/2 trial of GMI-2171
are very encouraging, demonstrating a high remission rate in both
patient populations being treated. In addition, the combination of
GMI-1271 and chemotherapy within the trial also seems to be extremely
well tolerated," said
Details of the ASH poster include:
Abstract #4049--A Phase I/II Study of GMI-1271, a Novel
E-Selectin Antagonist, in Combination with Induction Chemotherapy in
Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid
Leukemia; Results to Date.
The poster is one of seven presentations on GlycoMimetics' drug
candidates being made at the ASH meeting. Data also was shared on
results of pre-clinical and clinical research on the pan-selectin
antagonist, rivipansel, which
The meeting abstracts are available at ASH's website.
About
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate, GMI-1271. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the initiation of future clinical trials, whether interim results
from a clinical trial will be predictive of the final results of the
trial or results of early clinical trials will be indicative of the
results of future trials, expectations for regulatory approvals,
availability of funding sufficient for GlycoMimetics' foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
other matters that could affect the availability or commercial potential
of GlycoMimetics' drug candidates and other factors discussed in the
"Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that
was filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20161205005798/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media